Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: GlobalData
|
$250.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
AnGes MG Inc Announces Positive Result of Step Two Clinical Trial of Cervical Portion Cancer Vaccine
AnGes MG Inc announced that the step two clinical trial of its cervical portion cancer vaccine is positive.
Latest Developments for Anges MG Inc
- AnGes MG Inc Announces Outcome Of Early Retirement Program; Announces Extraordinary Loss for FY 2013
- AnGes MG Inc Expects Extraordinary Profit and Extraordinary Loss for FY 2012; Amends Consolidated Full-year Forecast for FY 2012
- AnGes MG Inc to Offer Early-retirement Program
- AnGes MG Inc to Sell Subsidiary to ISHIHARA SANGYO KAISHA LTD
Latest Key Developments in Biotechnology
- DURECT Corp Announces FDA Acceptance Of New Drug Application (NDA) Submission For Posidur
- PTC Therapeutics Inc Prices Initial Public Offering
- Cardio3 Biosciences SA Launches IPO-Reuters
- Cyprotex plc Sees H1 2013 Guidance To Exceed Board's Expectations; Sees FY 2013 Operating Profit Guidance In Line With Current Market Expectations
- Share this
- Link this
- Digg this
Follow Reuters